Claims for Patent: 7,709,477

Summary for Patent: 7,709,477

Title:	Methods for treating cancer
Abstract:	The present invention relates to novel Triheterocyclic Compounds, compositions comprising a Triheterocyclic Compound, and methods useful for treating or preventing cancer or a neoplastic disorder comprising administering a Triheterocyclic Compound. The compounds, compositions, and methods of the invention are also useful for inhibiting the growth of a cancer cell or neoplastic cell, treating or preventing a viral infection, or inhibiting the replication and/or infectivity of a virus.
Inventor(s):	Attardo; Giorgio (Vimont, CA), Lavallee; Jean-Francois (Mille-Iles, CA), Rioux; Elise (Laval, CA), Tripathy; Sasmita (Pierrefonds, CA), Doyle; Terrence W. (Killingworth, CT)
Assignee:	Gemin X Pharmaceuticals Canada Inc. (Montreal, CA)
Application Number:	12/176,161
Patent Claims:	1. A method for treating cancer in a patient, the method comprising administering to a patient in need thereof an effective amount of the compound whose structure is ##STR00082## or a pharmaceutically acceptable salt thereof, wherein the cancer is cervical cancer, prostate cancer, colon cancer, breast cancer, acute myelocytic leukemia, chronic lymphocytic leukemia, Non-Hodgkin's disease lymphoma, Hodgkin's disease lymphoma, acute lymphocytic leukemia, small cell lung cancer, follicular lymphoma, or non-small cell lung cancer. 2. The method of claim 1 further comprising administering a chemotherapeutic agent. 3. The method of claim 1, wherein the pharmaceutically acceptable salt is tartrate salt or mesylate salt. 4. The method of claim 2, wherein the chemotherapeutic agent is a nitrogen mustard, nitrosourea, alkylsulphonate, triazene, platinum containing compound, vinca alkaloid, taxoid, epipodophyllin, mytomycin C, DHFR inhibitor, IMP dehydrogenase inhibitor, ribonucleotide reductase inhibitor, uracil analog, cytosine analog, purine analog, anti-estrogen, LHRH agonist, anti-androgen, vitamin D3 analog, photodynamic therapy, cytokine, isoprenylation inhibitor, dopaminergic neurotoxin, kinase inhibitor, actinomycin, bleomycin, anthracycline, MDR inhibitor, or Ca.sup.2+ ATPase inhibitor. 5. The method of claim 2, wherein the chemotherapeutic agent is methotrexate, mercaptopurine, thioguanine, hydroxyurea, cytarabine, cyclophosphamide, ifosfamide, nitrosoureas, cisplatin, carboplatin, mitomycin, dacarbazine, procarbizine, etoposide, campathecins, bleomycin, doxorubicin, idarubicin, daunorubicin, dactinomycin, plicamycin, mitoxantrone, asparaginase, vinblastine, vincristine, vinorelbine, paclitaxel, cytosine arabinoside, or docetaxel. 6. The method of claim 1, further comprising administering radiation therapy. 7. The method of claim 1, wherein the cancer is small cell lung cancer, follicular lymphoma, non-small cell lung cancer, non-Hodgkin's disease lymphoma, or acute myelocytic leukemia. 8. The method of claim 1, wherein the cancer is small cell lung cancer.

Details for Patent 7,709,477

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Recordati Rare Diseases, Inc.	ELSPAR	asparaginase	For Injection	101063	01/10/1978		2023-05-30